You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.


Has apotex already filed ruxolitinib anda in us?

See the DrugPatentWatch profile for ruxolitinib

Based on the information available, it is not explicitly stated whether Apotex has already filed a generic version of Ruxolitinib in the US. However, according to, the patent for Ruxolitinib (trade name Jakafi) expired on November 14, 2020 [1]. This means that Apotex or any other pharmaceutical company can now file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) to produce a generic version of Ruxolitinib [2].

It's important to note that the filing of an ANDA does not guarantee approval from the FDA. The FDA reviews the application to ensure that the generic drug is equivalent to the already approved drug in terms of safety, effectiveness, strength, stability, and quality [3].

Therefore, while Apotex or any other company could have filed an ANDA for Ruxolitinib, it is not publicly known if they have done so.


Other Questions About Ruxolitinib :  When did apotex s ruxolitinib version receive fda approval? What is the exact fda submission date for apotex s ruxolitinib? When did apotex first submit their ruxolitinib application?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy